StemCell Therapy

PALO ALTO, Calif.--(BUSINESS WIRE)--NTT Research, Inc., a division of NTT (TYO:9432), today announced that its Medical and Health Informatics (MEI) Lab has entered a joint research agreement with the Technical University of Munich (TUM) to work on three-dimensionally transformable and implantable electrodes. Dr. Hitonobu Tomoike (M.D., Ph.D.), a renowned scientist and medical researcher, directs the MEI Lab, which will be collaborating with Dr. Bernhard Wolfrum, Professor of Neuroelectronics at TUM in the Department of Electrical and Computer Engineering and the Munich School of BioEngineering (MSB). The scope of work for this multi-year project includes screening and optimizing functional materials, assembling 3D structures, and evaluating their biocompatibility.

Charged with discovering technologies that can revolutionize patient care, the NTT Research MEI Lab is focusing on the transformation and miniaturization of medical device components. This joint research will address the tendency of conventional electronics to work against and at a relative distance from, rather than with and alongside their targeted organ or tissue. The flexible micro- or nano-scale electrodes envisioned as an outcome of this project are expected to minimize the negative impact that rigid and planar electrode materials have on soft and curvilinear biological samples.

In order to acquire in vivo biological signals stably, with a high accuracy for a long period of time, a flexible electrode with high biocompatibility is required, said Dr. Tomoike. To achieve this, we will use nano and micro-scale conductive polymer thin films that are friendly to living bodies and consider the use of in vivo implant electrodes, as well as the control of structural changes of the functional electrodes in the body.

The two principal researchers bring considerable expertise to this project. Dr. Tomoike, former Director of the Sakakibara Heart Institute, Director Emeritus at the National Cerebral and Cardiovascular Center in Japan, and former Professor of Cardiology at Yamagata University, is known for his work in precision medicine involving bio-sensors and analytics. Dr. Wolfrums research focuses on neuro- and bioelectronics. He has developed electrochemical sensor arrays and interfaces to cellular networks and employed microfabrication techniques, advanced printing technologies, and microfluidic cell culture methods with the goal of establishing neuroelectronic hybrids and systems for on-chip neuroscience and bioelectronic medicine.

The Technical University of Munich has strengths in neuron growth control and electrophysiological measurement and has recently accumulated know-how and knowledge of printing technology for bioelectronics, said Dr. Tomoike, who is also a Fellow of the American College of Cardiology and of the American Heart Association. We are aiming for breakthroughs in fundamental material science and unprecedented technologies for diagnostic, therapeutic and surgical functions.

Along with pursuing ambitious research targets, this agreement also advances NTT Researchs goal of engaging with partners around the world. As part of this project, NTT Research MEI Lab will send two of its researchers to Munich. The MEI Lab also plans to open an office in Germany. The research will officially launch in Q1 2020; the first phase of the project may take as long as three years.

We are very pleased to have entered this long-term joint research agreement with the MEI Lab of NTT Research and believe our combined strengths will lead to promising advances in a critically important field of bioengineering, said Dr. Wolfrum, who conducted postdoctoral research in nanoscience at Delft University, has led a research group at the Peter Grnberg Institute in Jlich, lectured at Aachen University, and conducted research as a visiting associate professor at Tohoku University in Sendai.

Throughout this interdisciplinary research project, the two organizations are expected to leverage their respective strengths. The Technical University of Munich, which is a member of the TU9 alliance of nine leading German institutes of technology, will be involved through its Neuroelectronics Group (NEL), Munich School of BioEngineering, in the investigation, characterization, and micro/nanofabrication of materials. For its part, the MEI Lab will design experiments and research targets and conduct data analysis based on IoT and AI technologies. Each party will assume roles in evaluating the biocompatibility of fabricated devices.

One notable aspect of this project, according to Dr. Tomoike, is its focus on the physics of soft nanomaterials, the self-assembly of which allows not only for precise control of 3D structures but also reversible transformation of electrodes that interface and function with cells and tissues. Possible applications involve sensing and stimulation electrodes for the brain and heart, brain-machine interfaces, multi-array electrodes for neuronal analysis, and new approaches to vasodilation.

About NTT Research

NTT Research opened its Palo Alto offices in July 2019 as a new Silicon Valley startup to conduct basic research and advance technologies that promote positive change for humankind. Currently, three labs are housed at NTT Research: the Physics and Information Science (PHI) Lab, the Cryptography and Information Security (CIS) Lab, and the Medical and Health Informatics (MEI) Lab. The organization aims to upgrade reality in three areas: 1) quantum information, neuro-science and photonics; 2) cryptographic and information security; and 3) medical and health informatics. NTT Research is part of NTT, a global technology and business solutions provider with an annual R&D budget of $3.6 billion.

NTT and the NTT logo are registered trademarks or trademarks of NIPPON TELEGRAPH AND TELEPHONE CORPORATION and/or its affiliates. All other referenced product names are trademarks of their respective owners. 2019 NIPPON TELEGRAPH AND TELEPHONE CORPORATION

More:
NTT Research and Technical University of Munich (TUM) Enter Joint Research Agreement to Collaborate on Technologies to Affect the Future of Patient...

A new type of micromotor has been developed. Directed by magnets and powered by ultrasound, these micromotors are capable of traveling across microscopic particles and cells in very crowded areas without causing any damage.

These microswimmers provide a new way to manipulate single particles with precise control and in three dimensions, without having to do special sample preparation, labeling, surface modification, said Joseph Wang, a professor of nanoengineering at University of California San Diego (USCD), in a UCSD press release.

Wang, Thomas Mallouk, a professor of chemistry at the University of Pennsylvania, and Wei Wang, professor of materials science and engineering at Harbin Institute of Technology, are credited as senior authors of a paper detailing the development of these micromotors. The study was published on Oct. 25 in Science Advances.

Researchers tested the technology by moving HeLa cells the oldest and most commonly used cell line for scientific research and silica particles in aqueous media with micromotors. They accomplished this task without damaging nearby particles and cells. In one test, the researchers were able to create letters by pushing particles with the micromotors. In another, they exerted control over the micromotors, making them climb up microscopic blocks and stairs. This test demonstrated that they were capable of navigating over three-dimensional objects.

The micromotors are essentially gold-coated hollow polymer structures that are shaped like a half capsule. Within the body of the micromotor is a tiny magnetic nickel nanoparticle, allowing them to be steered with magnets. The inside surface is treated so it can repel water, so when the micromotor is submerged in water, an air bubble is trapped inside the device. This trapped bubble is integral to the functioning of the micromotor, as it allows the micromotor to respond to ultrasound. Upon receiving ultrasound waves, the trapped bubble begins to oscillate, forming forces that give it an initial push to movement. By applying an external magnetic field, it can move continuously, while altering the direction of the field allows researchers to control the speed and trajectory of the micromotors.

We have a lot of control over the motion, unlike a chemically fueled micromotor that relies on random motion to reach its target, said Fernando Soto, a nanoengineering Ph.D. student studying at UC San Diego. Also, ultrasound and magnets are biocompatible, making this micromotor system attractive for use in biological applications.

The authors plan on making improvements to the micromotors in the coming years. For example, they want to make them more biocompatible using biodegradable polymers and a magnetic material that is less toxic, such as iron oxide. Thanks to this technology, the researchers have opened new possibilities for nanomedicine, tissue engineering, targeted drug delivery, regenerative medicine, and other applications in the field of biochemistry.

See the original post here:
Micromotors move single cells using magnets and ultrasound - CMU The Tartan Online

The Healthcare Nanotechnology Market report delivers a comprehensive overview of the crucial elements of the market and elements such as drivers, current trends of the past and present times, supervisory scenario & technological growth. The report provides useful insights into a wide range of business aspects such as pillars, features, sales strategies, planning models, in order to be enable readers to gauge market scope more proficiently.

Healthcare Nanotechnology Report is based on exploratory techniques like qualitative and quantitative analysis to uncover and present data on the target market. Efficient sales strategies have been mentioned that would business and multiply customers in record time.

The major manufacturers covered in this report:

Amgen

Teva Pharmaceuticals

Abbott

UCB

Roche

Celgene

Sanofi

Merck & Co

Biogen

Stryker

Gilead Sciences

Pfizer

3M Company

Johnson & Johnson

Smith & Nephew

Leadiant Biosciences

Kyowa Hakko Kirin

Shire

Ipsen

Endo International

Sample/Inquire at:

https://www.marketinsightsreports.com/reports/01161054970/global-healthcare-nanotechnology-market-size-status-and-forecast-2019-2025/inquiry?source=MW&mode=82

Healthcare Nanotechnology Market Product Type:

Nanomedicine

Nano Medical Devices

Nano Diagnosis

Other

Healthcare Nanotechnology Market Applications:

Anticancer

CNS Product

Anti-infective

Other

Healthcare Nanotechnology Market Report has been studied and presents an actionable idea to key contributors working in it. The report integrates several drivers as well as factors that impede the growth of this market during the forecast to 2019-2025. An extensive qualitative analysis of factors responsible for driving the market growth and future opportunities has been provided in the market overview section.

Avail Upto 20% Discount On This Report At:

https://www.marketinsightsreports.com/reports/01161054970/global-healthcare-nanotechnology-market-size-status-and-forecast-2019-2025/discount?source=MW&mode=82

This report covers regional analysis including several regions such as North America, Europe, Asia Pacific, Middle East & Africa and Latin America. It focuses on the leading and the progressing countries from every region in detail. South East Asia, Japan, China, and India are also predictable to witness vigorous growth in their respective markets for Global Healthcare Nanotechnology Market in the near future, states the research report.

Important Features that are under Offering and Key Highlights of the Reports:

Detailed overview of Healthcare Nanotechnology Market Changing market dynamics of the industry In-depth market segmentation by Type, Application etc. Historical, current and projected market size in terms of volume and value Recent industry trends and developments Competitive landscape of Healthcare Nanotechnology Market Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth

Browse Full Report at:

https://www.marketinsightsreports.com/reports/01161054970/global-healthcare-nanotechnology-market-size-status-and-forecast-2019-2025?source=MW&mode=82

A thorough study of the competitive landscape of the Global Healthcare Nanotechnology Market has been given, presenting insights into the company profiles, financial status, recent developments, mergers and acquisitions, and the SWOT analysis. This research report will give a clear idea to readers about the overall market scenario to further decide on this market project.

We also offer customization on reports based on specific client requirement:

1- Country level analysis for any 5 countries of your choice.

2- Competitive analysis of any 5 key market players.

3- 40 analyst hours to cover any other data points

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights ReportsPhone: + 1704 266 3234 | +91-750-707-8687sales@marketinsightsreports.com | irfan@marketinsightsreports.com

Link:
Healthcare Nanotechnology Market Needs and Demand Analysis 2019 to 2025 - The Chicago Sentinel

Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer. Some of the recent clinical efforts are being targeted at the molecular level characterization of triple-negative breast cancer across emerging therapeutic targets such as epigenetic proteins, PARP1, androgen receptors, receptor and non-receptor tyrosine kinases, and immune checkpoints. These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market. In a new research study, Persistence Market Research estimates the globaltriple-negative breast cancer treatment marketrevenue to cross US$ 720 Mn by 2026 from an estimated valuation of just under US$ 505 Mn in 2018. This is indicative of a CAGR of 4.7% during the period 2018 to 2026.

Development of generics is another key opportunity area in the triple-negative breast cancer treatment market. With the rapidly expanding number of cancer cases across the world, there is a need for effective cancer management, including the provision of better and more efficient drugs. Developing economies are faced with challenges on several fronts including paucity of funds and lack of proper treatment options, calling for more innovative approaches to affordable healthcare. The availability of biosimilars and affordable generic anti-cancer drugs in developing regions is expected to significantly reduce the burden of cancer care. A projected cost reduction to the tune of more than 30% 40% and extended use of generic drugs is expected to reduce overall cancer treatment costs, thereby increasing the treatment rate for triple-negative breast cancer. This is further anticipated to create lucrative growth opportunities in the global triple-negative breast cancer treatment market.

Advances in Cancer Treatment and Introduction of Innovative Cancer Treatment Drugs to Boost Revenue Growth of the Triple-Negative Breast Cancer Treatment Market

Breast cancer is one of the most common types of cancer in women, and over the years, pharmaceutical and life sciences companies have been conducting advanced research and development activities to devise newer treatment options and drugs to treat breast cancer. Several new drug formulations are currently in the pipeline in different stages of clinical development and this is expected to bode well for the triple-negative breast cancer treatment market. Innovation in oncology therapeutics has shifted focus towards an outcome based approach to cancer care, with an increasing emphasis on combination drugs and newer therapeutic modalities. This is further likely to put the global triple-negative breast cancer treatment market on a positive growth trajectory in the coming years.

Combination Therapy and Advancements in Nano Medicine Research Trending the Triple-Negative Breast Cancer Treatment Market

One of the biggest trends being observed in the global market for triple-negative breast cancer treatment is the shift towards combination therapy. Companies in the global triple-negative breast cancer treatment market are conducting clinical trials for combination therapies by collaborating with other players in the market. Combination therapies are the latest innovation in the field of oncology and the combination of therapeutic drugs with chemotherapy is said to be an effective protocol for the treatment of triple-negative breast cancer.

Another huge trend in the triple-negative breast cancer treatment market is the emergence of nanotechnology as an efficient tool in the clinical management of critical diseases such as triple-negative breast cancer. It has been observed that the combination of gold nanoparticles and folic acid results in higher cell entry rate in both in-vitro and in-vivo models, indicative of the fact that folate receptors are effective targeted therapies for the treatment of triple-negative breast cancer. Nanoparticles facilitate systematic and efficient delivery of drugs and agents to the site of the tumor. Advanced R&D in nanotechnology and nano medicine is one of the top trends likely to impact the global triple-negative breast cancer treatment market in the years to come.

Go here to see the original:
Triple Negative Breast Cancer Treatment Market Rapid Industrialization To Boost Growth By 2018 to 2026 - Zebvo

A 1989 paper by Russian researcher Dmitrii Kuznetsov on the genetics of wild timber voles has been retracted, decades after a scientist alerted the journal to concerns, according to Retraction Watch. The paper, published in the International Journal of Neuroscience, has been touted by creationists as evidence of their beliefs, and Kuznetsov has repeatedly been accused of scientific misconduct, The Scientist reported in 2013.

In the paper, Kuznetsov reportedly identified an mRNA from one vole species that blocked protein synthesis in a related vole species. That same mRNA, however, did not block translation in the original vole species or another species that was more distantly related. The finding, Kuznetsov wrote in his report, supported the general creationist concept on the problems of the origin of boundless multitudes of different and harmonically functioning forms of life.

Five years after the paper was published, Dan Larhammar, a cell and molecular biologist at Uppsala University in Sweden, wrote to the journal editors discounting Kuznetsovs paper, saying his approach goes against established scientific experience and his claimed results are not qualitatively demonstrated, and that Kuznetsovs critique of a modern molecular-genetic concept of biological evolution has no scientific basis whatsoever. Larhammar learned last year that despite his criticism more than two decades earlier, Kuznetsovs paper was still available without a retraction label, he tells Retraction Watch, which was especially concerning given that repeated accusations of fraudallegedly making up citations and fabricating the sources of samplesled to Kuznetsovs ouster as editor-in-chief of two journals in 2013.

After a series of emails between Larhammar, now president of the Royal Swedish Academy of Sciences, and the International Journal of Neurosciences editor, the Kuznetsov paper now has a retraction stamp, which states: The above article has been retracted due to the unreliable nature of the experimental results presented.

Ashley Yeager is an associate editor at The Scientist. Email her at ayeager@the-scientist.com.

Read the original post:
Paper Used in Creationist Teaching Retracted After 30 Years - The Scientist

BETHESDA, Md., Nov. 13, 2019 /PRNewswire/ --The American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen) have released an important new joint consensus recommendation that will guide the evaluation of constitutional copy number variants (CNVs), encourage consistency and transparency across clinical laboratories, and lead to improved quality of patient care.

The extensive and detailed recommendation, "Technical standards for the interpretation and reporting of constitutional copy number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen)," is the result of a joint collaborative working group of ACMG and ClinGen, working together since 2015, to update the existing ACMG clinical laboratory practice standards for evaluating CNVs. Copy number analysis is recommended as a first-tier approach for the evaluation of individuals with neurodevelopmental disorders, such as intellectual disability, developmental delay and autism spectrum disorder, as well as for individuals with multiple congenital anomalies and for fetuses with ultrasound abnormalities.

"It is our hope that having standards that are widely available, up to date, and flexible enough to incorporate lessons learned from the ever-evolving clinical genomics knowledge base will help to reduce discordance in clinical classifications and will improve clinical care," said Christa Lese Martin, PhD, FACMG, the paper's senior author.

The recommendation represents a significant update from previous recommendations published in 2011 entitled "American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants," and is intended to complement the widely cited 2015 paper for sequence variants, "Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology."

The updated technical standards include several major changes from the previous document. The first major change is using the same five-tier system used in sequence variant classification: pathogenic, likely pathogenic, uncertain significance, likely benign, and benign. The previous standards recommended utilizing "likely pathogenic" and "likely benign" as sub-categories under "uncertain significance" (essentially a 3-tier system). Harmonizing copy number and sequence variant terminology will become increasingly important as the identification and classification of both types of variants within a single platform becomes more commonplace.

The second major change encourages laboratories to uncouple the classification of the variant from the clinical significance for the patient. While the patient's phenotype may be an important piece of evidence to consider when determining the classification of the variant, it should not override other evidence for or against the pathogenicity of the variant, and it should not be used to justify different classifications of the same variant in different individuals. For example, loss of function variants in a particular gene are known to cause hearing loss; there is enough evidence to warrant calling deletions of this gene pathogenic. A deletion of this gene in an individual not reported to have hearing loss should not be called "uncertain significance" solely because hearing loss was not their reason for referral; this could represent an incidental finding with potential implications for the individual's future health, or a cause for a phenotype that was not reported. The practice of changing the variant classification based on whether it explained the stated reason for referral has the potential to result in both inter- and intra-laboratory variant classification discrepancies; this change is intended to help reduce this issue.

The most substantial change is the incorporation of points-based scoring metrics to systematically guide laboratories through the classification of copy number losses and gains. In this scoring system, the various types of evidence considered when evaluating CNVs are awarded points based on their relative strengths, with positive point values for evidence for pathogenicity and negative point values for evidence against pathogenicity. At the end of the evaluation, the sum of all accumulated points leads to a suggested classification. "The scoring metrics are intended to be a guide to provide more structure and transparency to the CNV evaluation," said Erin Rooney Riggs, MS, CGC, the paper's lead author. "We have developed this type of quantitative metric for other types of curation within ClinGen which are being used successfully to increase consistency in data interpretation. With education and experience, we anticipate that the use of these metrics, as well as the other recommendations in these updated technical standards, will lead to increased consistency in constitutional CNV classification."

The recommendation states, "Although these standards attempt to comprehensively incorporate commonly available resources and processes used in CNV classification and interpretation, it is important to recognize that no singular algorithm will be applicable in all potential scenarios.The semi-quantitative scoring framework is meant to serve as a guide. Professional judgment should always be used when evaluating the evidence surrounding a particular genomic variant and assigning a classification."

The working group and authors on the new joint consensus recommendations include: Erin Rooney Riggs, MS, CGC; Erica F. Andersen, PhD; Athena M. Cherry, PhD; Sibel Kantarci, PhD; Hutton Kearney, PhD; Ankita Patel, PhD; Gordana Raca, MD, PhD; Deborah I. Ritter, PhD; Sarah T. South, PhD; Erik C. Thorland, PhD; Daniel Pineda-Alvarez, MD; Swaroop Aradhya, PhD and Christa Lese Martin, PhD.

About the American College of Medical Genetics and Genomics (ACMG) and ACMG Foundation for Genetic and Genomic Medicine

Founded in 1991, the American College of Medical Genetics and Genomics (ACMG) is the only nationally recognized medical society dedicated to improving health through the clinical practice of medical genetics and genomics and the only medical specialty society in the US that represents the full spectrum of medical genetics disciplines in a single organization. The ACMG is the largest membership organization specifically for medical geneticists, providing education, resources and avoice for more than 2,300 clinical and laboratory geneticists, genetic counselors and other healthcare professionals, nearly 80% of whom are board certified in the medical genetics specialties. ACMG's mission is to improve health through the clinical and laboratory practice of medical genetics as well as through advocacy, education and clinical research, and to guide the safe and effective integration of genetics and genomics into all of medicine andhealthcare,resulting in improved personal and public health. Four overarching strategies guide ACMG's work: 1) to reinforce and expand ACMG's position as the leader and prominent authority in the field of medical genetics and genomics, including clinical research, while educating the medical community on the significant role that genetics and genomics will continue to play in understanding, preventing, treating and curing disease; 2) to secure and expand the professional workforce for medical genetics and genomics; 3) to advocate for the specialty; and 4) to provide best-in-class education to members and nonmembers. Genetics in Medicine, published monthly, is the official ACMG peer-reviewed journal. ACMG's website (www.acmg.net) offers resources including policy statements, practice guidelines, educational programs and a 'Find a GeneticService' tool. The educational and public health programs of the ACMG are dependent uponcharitable gifts from corporations, foundations and individuals through the ACMG Foundation forGenetic and Genomic Medicine.

About the Clinical Genome Resource

The Clinical Genome Resource (ClinGen)is a National Institutes of Health (NIH)-funded resourcededicated to building an authoritative central resource that defines the clinical relevance of genesand variants for use in precision medicine and research. Since 2012, ClinGen has worked tofacilitate responsible genomic and phenotypic data sharing between clinicians, clinicallaboratories, researchers, and patients; to develop and implement standards to support clinicalannotation and interpretation of genes and variants; to enhance and accelerate expert review ofthe clinical relevance of genes and variants; and to disseminate and integrate ClinGen knowledgeand resources to the broader community. ClinGen is primarily funded by the National HumanGenome Research Institute (NHGRI) through the following three grants: U41HG006834,U41HG009649, and U41HG009650.

Kathy Moran, MBA

kmoran@acmg.net

SOURCE American College of Medical Genetics and Genomics

http://www.acmg.net

Read more here:
Important New Joint Consensus Recommendation from the ACMG and ClinGen Provides Technical Standards for the Interpretation and Reporting of...

By Osmel Ramirez Alvarez

HAVANA TIMES I have quite a few intellectual projects on the backburner because Ill have a bit more time in the future: many interesting and useful books that I would like to read and I cant get a few pages in; jobs around the house that demand my attention; and dozens of other things that I put off for a bit or entirely because I prioritize whats important, urgent.

The three most pressing things right now are:

First of all, support my family with the basic, at least, because I have three children, a wife who depends on me financially, and I even have to support my parents from time to time. A great odyssey, theres no doubt about that, in this difficult country, where peoples work is the only dirt-cheap thing there is here.

Secondly, trying to be useful to my country, to the change that Cuba needs to move towards a democracy, contributing ideas, pushing consensus among Cubans, helping people to understand our complex reality and cooperating to try and get our citizens active in public affairs.

Its just that I dream of a better country, where we wouldnt need to emigrate or steal in order to have what we dream of and in order for that to be a possibility, we have to stop delegating responsibility and learn to take part ourselves.

Third of all, its my life mission to be happy, or as happy as I can be amidst all of these problems. Keeping myself as healthy as I can in both body and mind, without hate, resentment, regrets and resignation. On the contrary, with a lot of resilience, faith in the future and confidence in the value of what I and we do. Without such a life philosophy, youd get dragged into the daily confusion and being efficient and proactive becomes impossible.

And where does farming come into all of this?

I really like agriculture, but more as a hobby. If I do it commercially, or to make a living, its because tough economic times force me to. As a result, it fits in with my three life priorities, which are the foundation of my life strategy.

I farm as an extra to make ends meet and support my family, because what I earn from my intellectual endeavors would only be enough to support myself, and it wouldnt be enough for my large family. But, its not a burden. My family is my oasis. My childrens and wifes love is an incomparable refuge. As well as my parents company, who live next to me or my sisters and nephews and nieces, cousins, aunts and uncles, everything, is extra. This is how I live my life, surrounded by family and I feel loved.

Quite regularly, someone who knows me will talk sadly when they see me farming, dirty sometimes, with my old palm leaf hat and old work clothes. They say things like: With everything you studied, its a crime that youre out here working the land. But I tell them that Im as happy out here in the field as I am when I was behind a microscope or a laminar flow bench in the labs when I worked as a biologist. I even sing when Im farming. But they dont get me.

I understand crops and the work it takes to get a good harvest, just like I know about the human anatomy, molecular genetics or ecology. I dont really think of myself as a farmer, because thats not my main identity. However, I have always had the countryside around me, ever since I was born. Even though my father and grandfather were workers, of trades and at a sugar mill respectively, they never broke all ties with farming.

We inherited two hectares of land from my grandmother, which she had inherited herself from her father, and he from his, my great-great-grandfather called Ramon Segura, a son of the Spanish who didnt support the Mambises in their cause, because he preferred to keep ties with Spain. That was his right. The 1902 Republic respected private property and it is still privately-owned today, being a horse ranch, and then divided among the descendants.

The alluvial soil is very fertile, one of the best in Cuba for tobacco farming (and Im not exaggerating). My plot isnt very big, in commercial terms, but it helps us to get by. It would be a great help if we were able to sow what we need to, but we cant because of high theft rates. Only tobacco, which you cant eat, and is hard to steal because of the process it needs to be of high commercial value, and little patches of other things.

I will plant tobacco again this year. My problems from two or three years ago still havent been completely resolved, which made this business riskier than gambling for me and I was forced to retire. However now the most important thing is that the company is valuing the product a lot more fairly because of a lapse in its production. And because there are very few options to invent on the side, Im trying to get a loan for a small plot, which is hard to do amid so much bureaucracy.

Read the rest here:
I Still Live Off the Land - Havana Times

This year there has been quite some talk about patenting the discovery of new genes. The patency eligibility criteria for this is set to undergo major reform in the US, which is likely to have a huge impact on a number of companies offering genetic testing kits, including 23andMe and AncestryDNA. Here, McDowell of EIP, an IP and patent law firm, shares her thoughts on the reform and the potential far-reaching impact it might have in the world of genetics, gene patenting and beyond.

The question of what should and should not qualify as patent eligible subject matter has, for several years, drawn sharp debate in the United States. Since 2012, the US Supreme Court has operated under the Alice/Mayo framework, which has sought to prevent patenting of abstract ideas and naturally occurring phenomena. This has had broad repercussions within the biotechnology sector and beyond; for example, resulting in the widespread proliferation of mail-order spit-kit operations like 23andMe.

Reform of the Alice/May framework has seen strong support from parts of the biotech industry, citing lack of investment as a barrier to greater research into diagnostic methods. However, a more general concern from stakeholders in the United States is that the unpredictability caused by the Alice/Mayo framework puts the US at a disadvantage compared to International competitors; particularly in respect of some of the most cutting-edge technologies, such as AI and molecular diagnostics. A lack of patent availability is allegedly driving investment to other countries, where such inventions are more clearly patent-eligible.

Battle lines have been drawn between the biotechnology and software industries, with calls for less restrictive eligibility criteria coming from the former. The financial input needed to develop new technologies differs substantially between these industries. Lone inventors and small businesses in the software industry, with the ability to develop their products cheaply, felt stifled by overbroad patents granted to others before 2012.

Meanwhile, even small players in the biotech industry rely on high value investment before diagnostic and curative treatments can be brought to patients. Intellectual property protection is key to ensuring that investors in this sector feel secure that the vast sums of money they contribute will be recouped through effective commercialisation.

The Executive Director of Cleveland Clinic Innovations recently explained that: Ability to gain patent protection is the first factor in our assessment of whether a product can reach the market; if an invention cannot get intellectual property protection, usually that is a fatal flaw and the invention is canned at that point.

With this being a widespread stance in the pharmaceutical and diagnostics industries, it is easy to see how the current restrictions to patentability could lead to fewer treatments being developed in the US. What is more, Internationally, the US is no longer top of the list for biopharma companies launching their products; with companies citing inability to protect their ideas as a key reason for not entering the US market.

On the other hand, there are those within the biotechnology sector who side with the software industry in favouring the status quo. Genetic testing companies have reaped the benefits of a restrictive patent eligibility criteria, which has resulted in the invalidation of patents to isolated gene products, and so removed the barriers to developing genetic testing kits.

Since 2013, aided by this provision, the cost of genetic testing kits has decreased significantly leading to a boom in popularity and numerous spit-kit companies have crowded the genetic testing market. This new Bill, if enacted, will likely prove problematic for US companies such as 23andMe, who offer customers the ability to test their DNA to uncover their ancestry or genetic vulnerabilities. Consequently, this might open the door for a widespread change in the industry.

The proposed Bill stuttered when a sticking point emerged during consultations with stakeholders. A last-minute amendment to 35 U.S.C. 112F, which governs how patentees may claim their invention in functional terms (as opposed to reciting specific physical structures), has been criticised by members of the biotech industry for watering down patent protections.

The draft Bill provided that, if any patent claim element is expressed as a specified function without the recital of structure, material, or acts in support thereof, then that claim element will be limited to the corresponding structure, material, or acts described in the specification and their equivalents.

This was offered to assuage concern that overruling the patent-eligible-subject-matter case law would herald a return of nuisance patents directed to business methods and software, which often contain functionally defined terms. However, rather than reassuring stakeholders in the software industry, the proposal seems to have succeeded mainly in frightening the biotechnology sector.

Several witnesses from both sides of the debate raised concerns about the burden that drafters and inventors will face from having to enumerate every way of carrying out a claimed method under the proposed amendment to 112F.

Conflicting views on the draft proposal has meant that the initial momentum for reform has been lost for the time being. This will frustrate those in the biotech industry who are keen to see a return the ability to obtain patent protection for their products and processes, which they hope will boost research, and drive investment back into the United States.

See original here:
Gene patenting reform in the US and the knock-on effect in Europe - Health Europa

We might refer to someones personality as mousy, but in truth, mice have a range of personalities nearly as great as our own. Prof. Alon Chen and members of two groups he heads one in the Weizmann Institute of Sciences Department of Neurobiology and one in the Max Planck Institute of Psychiatry in Munich, Germany decided to explore personality specifically in mice. This would enable the scientists to develop a set of objective measurements for this highly slippery concept. A quantitative understanding of the traits that make each animal an individual might help answer some of the open questions in science concerning the connections between genes and behavior. The findings of this research were published in Nature Neuroscience.

Each mouse could be seen to have a unique, individual personality that consistently informed its behavior.

Dr. Oren Forkosh, then a postdoctoral fellow who led the research in Prof. Chens group in Germany, explains that understanding how genetics contribute to behavior has remained an open question. Personality, scientists hypothesized, might be the glue that binds the two together: both genes and epigenetics (which determines how the genes are expressed) contribute to personality formation; in turn, ones personality will determine, to a great extent, how one behaves in any given situation.

Personality is, by definition, something that is individual for each animal and something that remains fairly stable for an animal over its lifetime. Human subjects are generally given personality scores based on multiple-choice questionnaires, but for mice, the researchers needed to start with their behavior and work backward. The mice were color-coded for identification, placed in small groups in regular lab environments with food, shelter, toys, etc. and allowed to interact and explore freely. These mice were videoed over several days, and their behavior analyzed in depth. All together, the scientists identified 60 separate behaviors, including approaching others, chasing or fleeing, sharing food or keeping others away from food, exploring or hiding.

Four mice in a well-stocked cage exhibited around 60 different behaviors for evaluation. Credit: Weizmann Institute of Science

Next, the team created a computational algorithm to extract personality traits from the data on the mices behavior. This method works something like the five-part personality score used for humans in which subjects are graded on sliding scales that rate extroversion, agreeableness, conscientiousness, neuroticism, and openness to experience. For mice, the algorithms the group developed revealed four such sliding scales, and although the researchers refrained from assigning anthropomorphic labels to these ratings, they can be applied very much like the human ones. That is, each scale is linear, with opposites at either end; when the group assigned the mice personality types based on their scores for these traits, they found that each mouse could be seen to have a unique personality that consistently informed its behavior. To see if these traits were indeed stable, the researchers mixed up the groups a stressful situation for the mice. They found that some of the behaviors changed sometimes drastically but what they had assessed as personality remained the same.

What can now be learned from a method for assessing a mouses personality? Working with Prof. Uri Alon of the Institutes Department of Molecular Cell Biology, the team used the linear scales they had developed to plot a personality space in which two of the traits were compared. This sort of analysis yields a triangle in which archetypes inhabit the corners (for example, highly dominant and non-commensal [country mice that are not human-friendly], dominant but commensal [city mice], and subordinate).

When traits are viewed this way, they can point to evolutionary tradeoffs for example, in the need to survive and thrive in a dominance hierarchy. In fact, says Dr. Forkosh, we see that these archetypes and all the shades in between are quite natural. These traits have not been bred out of our mice, even though they have lived for generations in labs and could probably not survive in the wild.

The researchers also mapped gene expression patterns in the brains of these mice, and found that they could identify a number that were associated with certain personality traits they had identified.

Based on the 60 behaviors, an algorithm found those relevant to personality, and mapped out four scales for assessing mouse personality. Credit: Weizmann Institute of Science

This method will open doors to all sorts of research, says Dr. Forkosh. If we can identify the genetics of personality and how our children inherit certain aspects of their personalities, we might also be able to diagnose and treat problems when these genes go wrong. We might even, in the future, be able to use these insights to develop more personalized psychiatry; for example, to be able to prescribe the proper treatments for depression. In addition, we can use the method to compare personality across species, and thus to gain insight into the animals that share our world.

###

Reference: Identity domains capture individual differences from across the behavioral repertoire by Oren Forkosh, Stoyo Karamihalev, Simone Roeh, Uri Alon, Sergey Anpilov, Chadi Touma, Markus Nussbaumer, Cornelia Flachskamm, Paul M. Kaplick, Yair Shemesh and Alon Chen, 4 November 2019, Nature Neuroscience.DOI: 10.1038/s41593-019-0516-y

Prof. Alon Chen is the President-Elect of the Weizmann Institute of Science. Also participating in this research were Stoyo Karamihalev, Sergey Anpilov, and Yair Shemesh of the Weizmann Institute of Science and the Max Planck Institute of Psychiatry; Markus Nussbaumer, Cornelia Flachskamm, Paul M. Kaplick, and Simone Roeh of the Max Planck Institute of Psychiatry; and Chadi Touma of the University of Osnabrck, Germany.

Prof. Alon Chens research is supported by the Vera and John Schwartz Professorial Chair in Neurobiology; the Ruhman Family Laboratory for Research in the Neurobiology of Stress; the Perlman Family Foundation, founded by Louis L. and Anita M. Perlman; the Fondation Adelis; Bruno Licht; and Sonia T. Marschak.

See original here:
Method for Measuring Animal Personality Developed to Explore Connections Between Genes and Behavior - SciTechDaily

Nes-Ziona, Israel, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (ENLV), a clinical-stage immunotherapy company, today announced that company management will make a corporate presentation and host 1x1 meetings at the 10th Annual Jefferies 2019 London Healthcare Conference, being held in London on November 20 & 21. The presentation is scheduled for November 20 2019 at 8:00am local time.

ALLOCETRATMby Enlivex was designed toprovide a novel immunotherapy mechanism of actionthat targets life-threatening clinical indications that are defined as unmet medical needs, includingprevention or treatment of complications associated with bone marrow transplantations (BMT) and/or hematopoietic stem cell transplantations (HSCT); organ dysfunction and acute multiple organ failure associated with sepsis; and enablement of an effective treatment of solid tumors via immune checkpoint rebalancing.

Enlivex announced on November 4, 2019 positive interim safety and efficacy data from an ongoing trial of off-the-shelf universal Allocetra in patients with severe sepsis. The interim analysis comparing Allocetra-treated patients with 37 severe sepsis patients with equivalent source of infection and disease severity who were hospitalized at the same hospital, demonstrated the potential of Allocetra as therapy for prevention of sepsis-associated organ failure and mortality.

For more information about the 10th Annual Jefferies 2019 London Healthcare Conference, visit http:// https://www.jefferies.com/IdeasAndPerspectives/Conferences/325/112019.

ABOUT ENLIVEXEnlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve an out of control immune system (e.g. Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing. For more information, visit http://www.enlivex.com.

ENLIVEX CONTACT:Shachar Shlosberger, CFOEnlivex Therapeutics, Ltd.shachar@enlivex-pharm.com

See the rest here:
Enlivex Therapeutics To Present At The 10th Annual Jefferies 2019 London Healthcare Conference - Yahoo Finance

Dr Alexandra Butler/Principal Investigator at Qatar Biomedical Research Institute, part of Hamad Bin Khalifa University, talks about efforts to tackle

What is diabetes?Diabetes is a disease that occurs when there is an inability to produce adequate amounts of insulin (a hormone produced by beta cells in the pancreas) to maintain blood glucose levels within normal limits, and it represents a major medical, social, and economic burden worldwide.The prevalence of diabetes has reached epidemic proportions globally, with 424.9mn affected adults aged 20-79, representing 8.8% of the global adult population.This figure is predicted to rise to 628.6mn by 2045, affecting almost 10% of the worldwide adult population. Type 2 diabetes accounts for 90 to 95% of diabetes cases, with type 1 diabetes accounting for about 5%. However, half of those with type 2 diabetes have not been diagnosed.In Qatar, 20% of the population is affected by diabetes (type 2 accounting for 90% of those) with a projected rise to 24% in the next two decades. Diabetes in Qatar affects all segments of society, from the young to the elderly, and places a significant social and economic burden on Qatari society.What is the difference between type 1 and type 2 diabetes, and are there other types?The reasons underlying the inability to produce adequate amounts of insulin depend upon the type of diabetes.Type 1 is essentially a total insulin deficiency due to the destruction of beta cells by the bodys immune system. Type 2 is a complex disease characterised by insulin resistance and insulin deficiency. The degrees of resistance and deficiency vary, but insulin deficiency is key to developing diabetes.Gestational diabetes is a form of diabetes that can develop during pregnancy as pregnancy is a state of increased insulin resistance and these women have a higher risk of developing type 2 diabetes later in life.There are also genetic defects of beta cell function and insulin action, such as Maturity Onset Diabetes of the Young (MODY).Some conditions, such as diseases of the exocrine pancreas, can cause secondary diabetes as can certain drugs, corticosteroids being a prime example.

What are the symptoms of diabetes?Those with type 1 diabetes may experience thirst, a frequent need to urinate, weight loss, fatigue, blurred vision, ketoacidosis (a life-threatening conditions where the body starts breaking down fat at a rapid rate), and infections.Type 2 diabetes can lead to thirst, frequent urination, and malaise, but symptoms are usually much milder and many individuals with type 2 diabetes do not know they have the disease until they are tested.In certain circumstances, it can be difficult to distinguish between type 1 and type 2 diabetes (see Table 1). Distinguishing the type of diabetes can be particularly difficult in younger patients who are treated with insulin, but clinically appear to have type 2 diabetes, and older patients with late onset of diabetes who require insulin and share characteristics of patients with type 1 diabetes where Latent Autoimmune Diabetes of Adulthood (LADA) should be considered.What role is Qatar Biomedical Research Institute (QBRI) playing in relation to diabetes research?The genetic risks for type 2 diabetes are likely to be different for Qataris compared to other Asians and Europeans. Therefore, identification of factors that are associated with the high prevalence of type 2 diabetes in the Qatari population is an important focus of ongoing research at the Diabetes Research Center (DRC) at Qatar Biomedical Research Institute (QBRI), part of Hamad Bin Khalifa University.Diabetic complications are costly, extremely difficult to manage, and lead to increased mortality rates. Diabetic patients are also at increased risk of neurological impairment and certain forms of cancer, so identifying biomarkers that predict the future development of diabetes and/or its related complications is imperative.Accordingly, biomarker discovery is a major focus of the ongoing research at the DRC. With the advent of stem cells, the concept of mimicking nature to generate new beta-cells to reverse diabetes has emerged, although more work needs to be done to allow for safe and effective therapy.In collaboration with the Harvard Stem Cell Institute, the Stem Cell group at DRC is working towards developing safe and effective stem cell-derived therapy to meet the needs of diabetic patients in Qatar.The underlying causes of insulin resistance are not addressed by any current therapy.The DRC is also investigating the mechanisms of insulin resistance to identify new targets for drug discovery. The mechanisms underlying the susceptibility of kidney, retina, peripheral nerve and arteries to damage in diabetes are yet to be proven, but the DRC has made advances towards understanding these. The centre is paving the way towards improved biomarkers and focused treatments, or precision medicine for diabetes, in order to tackle this globally devastating disease.

Can we prevent or reverse diabetes if we follow a healthy lifestyle?In the Gulf region, the diabetes epidemic is largely fuelled by obesity and sedentary lifestyles. Type 1 diabetes is not reversible but type 2 is largely preventable and can be reversed in its earlier stages by adopting a healthy lifestyle, the mainstays of which include regular exercise, a healthy diet and maintaining a healthy weight.Anyone can suffer from diabetes and those with affected family members are at an increased risk. It is therefore a good idea to follow your doctors advice as to the frequency of testing for diabetes.

See the rest here:
Diabetes has reached epidemic proportions, yet many don't know they suffer from it - Gulf Times

Get your news fix on happenings outside the pool with the latest Beyond the Lane Lines. With each edition, we collect personal stories, little known facts and general items of interest from around the world. Read on and learn something new this week.

#1 Joseph Schooling Launches Skincare Line

Olympian Joseph Schooling took gold in the mens 100m fly at the 2016 Games in Rio and has been a superstar in his home nation ever since. The 24-year-old former Texas Longhorns latest accomplishment is taking place outside the pool, where the Singaporean just launched his own line of skincare products.

Teaming up with aesthetic doctor Dr. SM Yuen from Atlas Medical Laser & Aesthetics Clinic, Schooling has helped create a range of unisex beauty products that he hopes will help educate consumers on the importance of taking care of their skin.

My teammates used to laugh at me because I was the only one on the team who moisturized. We used to have our training [sessions] at the Toa Payoh pool where the chlorine level was super high. When I got out of the pool, my skin looked ashy and flaky. Our hair used to be bleached blonde and I had white patches all over my body and neck, said Schooling. So at age 11, taking care of my skin became a daily routine. It was something I had to do, otherwise, Id feel uncomfortable.

The result of Schoolings self-care experience isJS Orphic, a four-pronged skincare range made up of his daily grooming essentials: Pore Care Splash-Away cleanser, My Favourite Skin Hydrator, UV Shield + Skin Protector, and Stem Cell + Snail Waterfall Serum.

Quotes courtesy of CNA Lifestyle.

#2 Ellie Challis &Katie Shanahan Shortlisted for One-to-Watch Award

15-year-old British swimmerKatie Shanahan has been making a name for herself as of late, with the City of Glasgow swimmer reaping half of her nations gold medals at this years European Youth Olympic Festival in Baku, Azerbaijan.

For her efforts, as well as her future promise, teen Shanahan has been shortlisted out of approximately 1,000 candidates for the annual SportsAid One-to-Watch Award

Ive achieved so much over the last year, but the highlight has to be being nominated for awards like this one with SportsAid, said Shanahan of her nomination.

It was such an amazing opportunity to compete at the European Youth Olympic Festival. I didnt even expect to medal, let alone break any records, especially because it was such a high-level meet.

I was also lucky to race at Mare Nostrum in Barcelona, but I knew that one was going to be completely different. I was coming up against Olympians, Commonwealth, and European champions and I was so pleased to be almost as fast as some of the swimmers I have always looked up to.

As for Ellie Challis, she, too, has been nominated for the award, following a record-breaking 2019 in the pool. The 15-year-old busted out the SB2 class 50m breast World Record at the British Para Swimming International Meet in Glasgow.

Its lovely to be recognised for the One-to-Watch Award and for all my achievements. Its really nice and its that recognition at such a young age that makes it so special for me.

The winner of the One-to-Watch Award will be revealed at the charitys Celebrate the Next event on Tuesday, November 19th.

Quotes courtesy of Scottish Swimming.

#3 Cate Campbell Joins Melanoma Awareness Campaign

Olympic championCate Campbell averted a melanoma scare in November 2018 when the Aussie had a mole removed, only to find out it was indeed cancerous. Since then, C1 has been on the awareness train, helping fellow Australian citizens be more skin-conscious and educated when it comes to the effects of the sun.

Most recently, Campbell has been named as teh face of Melanoma Institute Australias Game On Mole campaign.

Says C1 of her ambassadorship, Im actually quite a private person, but I only went and got a skin check after running into someone who had their own melanoma story to tell.

If I hadnt met them on the off chance, would I have gone for that skin check?

Id like to think so, but I cant be sure and I may still be walking around with melanoma in my arm possibly heading into my bloodstream, which could have caused more complications than just a scar.

So I felt like I had an obligation to share my story and to be a part of the Game On Mole campaign.

If by sharing you can save one person, or if one person hears the story and goes and gets their skin checked, then I think that thats a win.

Quotes courtesy of Perth Now.

#4 Katie Ledecky Joins Team Visa

Worldwide Payment Technology Partner of the Olympic and Paralympic Games, Visa, announced its roster of athletes on Team Visa Tokyo 2020. The more than 70 athletes span 30 sports and represent 43 nations, the most in Team Visa history.

As one of the longest-standing partners of the Olympic and Paralympic Games, Visa looks forward to Tokyo 2020. Set to be the largest Games yet, Tokyo 2020 will feature 7,000 hours of broadcast programming and three billion minutes of streamed content, said Chris Curtin, chief brand and innovation marketing officer, Visa.

Our Team Visa Tokyo 2020 roster reflects The Games themselves: globally diverse, representative of new emerging sports and larger than ever. We are proud to reveal this years Team Visa roster and support these athletes as go for Gold in Tokyo.

Founded in 2000, Team Visa has championed nearly 500 athletes. Each has been selected based on athletic achievements, character and personal journey, and is representative of many of Visas brand values and priorities.

American Olympic icon Katie Ledecky has been named to the Visa roster, along with Adam Peaty of Great Britain, Florian Wellbrock of Germany, Daiya Seto and Kanako Watanabe of Japan, Dmitriy Baladin of Kazakhstan, Tatjana Schoenmaker of South Africa, Gregorio Paltrinieri of Italy, Daniel Dias of Brazil, Aurlie Rivard of Canada,Teresa Perales of Spain andYelyzaveta Mereshko of Ukraine.

Read the original here:
Beyond The Lane Lines: Schooling Launches Skincare, Ledecky Joins A New Team - SwimSwam

Myelofibrosis or osteomyelofibrosis is a myeloproliferative disorder which is characterized by proliferation of abnormal clone of hematopoietic stem cells. Myelofibrosis is a rare type of chronic leukemia which affects the blood forming function of the bone marrow tissue. National Institute of Health (NIH) has listed it as a rare disease as the prevalence of myelofibrosis in UK is as low as 0.5 cases per 100,000 population. The cause of myelofibrosis is the genetic mutation in bone marrow stem cells. The disorder is found to occur mainly in the people of age 50 or more and shows no symptoms at an early stage. The common symptoms associated with myelofibrosis include weakness, fatigue, anemia, splenomegaly (spleen enlargement) and gout. However, the disease progresses very slowly and 10% of the patients eventually develop acute myeloid leukemia. Treatment options for myelofibrosis are mainly to prevent the complications associated with low blood count and splenomegaly.

To Remain Ahead Of Your Competitors, Request for a Sample Here @https://www.persistencemarketresearch.com/samples/11341

The global market for myelofibrosis treatment is expected to grow moderately due to low incidence of a disease. However, increasing incidence of genetic disorders, lifestyle up-gradation and rise in smoking population are the factors which can boost the growth of global myelofibrosis treatment market. The high cost of therapy will the growth of global myelofibrosis treatment market.

The global market for myelofibrosis treatment is segmented on basis of treatment type, end user and geography:

As myelofibrosis is considered as non-curable disease treatment options mainly depend on visible symptoms of a disease. Primary stages of the myelofibrosis are treated with supportive therapies such as chemotherapy and radiation therapy. However, there are serious unmet needs in myelofibrosis treatment market due to lack of disease modifying agents. Approval of JAK1/JAK2 inhibitor Ruxolitinib in 2011 is considered as a breakthrough in myelofibrosis treatment. Stem cell transplantation for the treatment of myelofibrosis also holds tremendous potential for market growth but high cost of therapy is foreseen to limits the growth of the segment.

On the basis of treatment type, the global myelofibrosis treatment market has been segmented into blood transfusion, chemotherapy, androgen therapy and stem cell or bone marrow transplantation. Chemotherapy segment is expected to contribute major share due to easy availability of chemotherapeutic agents. Ruxolitinib is the only chemotherapeutic agent approved by the USFDA specifically for the treatment of myelofibrosis, which will drive the global myelofibrosis treatment market over the forecast period.

Geographically, global myelofibrosis treatment market is segmented into five regions viz. North America, Latin America, Europe, Asia Pacific and Middle East & Africa. Northe America is anticipated to lead the global myelofibrosis treatment market due to comparatively high prevalence of the disease in the region.

For Critical Insights On Keyword Market, Request For Customization Here @https://www.persistencemarketresearch.com/request-customization/11341

Some of the key market players in the global myelofibrosis treatment market are Incyte Corporation, Novartis AG, Celgene Corporation, Mylan Pharmaceuticals Ulc., Bristol-Myers Squibb Company, Eli Lilly and Company, Taro Pharmaceuticals Inc., AllCells LLC, Lonza Group Ltd., ATCC Inc. and others.

Go here to see the original:
Myelofibrosis Treatment Market To Witness an Outstanding Growth During 2016-2022 - Zebvo

Third Quarter Revenue Grew 34% Over the Prior Years Quarter and 25% Year to Date

Acquired BioPharma Business in Partnership with Ampersand

Diagnostic Test Volume Grew 16% for the Quarter and 22% Year to Date

Conference Call and Webcast Wednesday November 13, 2019 at 4:30 pm ET

PARSIPPANY, NJ, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (formerly Interpace Diagnostics Group, Inc.) (Nasdaq: IDXG), a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications, announced today that it has changed its name to Interpace Biosciences, Inc. to better reflect its new business model that combines its traditional esoteric molecular diagnostic business with its recent acquisition of the BioPharma business of Cancer Genetics (CGIX), now known as Interpace Pharma Solutions, that uses its proprietary test systems and platforms to support drug discovery and development valued by pharmaceutical and biotechnology companies. Interpace Biosciences will continue to trade on NASDAQ as IDXG.

Interpace Biosciences recognized $7.7 million in Net Revenue for the quarter and $20.0 million year to date. Our Diagnostics business had volume growth of 16% for the quarter and 22% year to date. Medicare and contracted reimbursement remained strong and continued to grow across both products.

On July 15, 2019 Interpace closed on the acquisition of the BioPharma business of Cancer Genetics and accordingly from that date forward the BioPharma business is being reported in the results of operations of Interpace Biosciences. Further, on October 16, 2019 Interpace Biosciences closed on the $13 million second tranche round of financing with Ampersand Capital Partners (Ampersand) and on October 24th we completed settlement with Cancer Genetics under the Net Working Capital Adjustment as planned. We are now moving forward together as one company!

Certainly part of our rationale in acquiring the BioPharma business was risk diversification of our customer base and revenue stream but more importantly it was to take advantage of the synergies between these two businesses as cancer therapeutics move toward earlier stage treatment, require customized services and obligate many therapeutic companies to match their targeted therapies with companion diagnostics. Today, Interpace Pharma Solutions is involved in over 225 clinical trials including approximately 47 immuno-oncology trials. Focusing on the Pharma Solutions business, contracts are growing and bookings have been recorded through September 30, 2019 worth over $18 million that are expected to be recognized over the next year or more. Our near-term growth plans are to add additional business development personnel in key unserved markets, expand our immuno-oncology franchise and accelerate global expansion as recently indicated by our partnership with Genecast in Bejing, China.

We think that the combination of the Interpace Diagnostics and Interpace Pharma Solutions businesses, now under the Interpace Biosciences umbrella, is a great platform to leverage our broad based and synergistic capabilities, and deliver consistent growth. The addition of Ampersand as a significant financial and strategic partner and investor in Interpace Biosciences we believe provides validation of our model and plans as well as the basis for supporting future synergistic growth. Interpace Biosciences has demonstrated its ability to not only acquire meaningful assets but to also cost effectively integrate assets while continuing to grow.

During the third quarter we continued to drive volume growth across our products and completed the acquisition of the BioPharma business of Cancer Genetics (CGIX). We are especially pleased to be partnering with Ampersand Capital Partners, one of the best known and most successful funds in the laboratory services space, said Jack Stover, President & CEO Of Interpace. The transition process is happening on schedule and our goal, as previously stated, is to reach adjusted EBITDA breakeven before the end of next year, Stover said.

THIRD QUARTER 2019 FINANCIAL PERFORMANCE

For the Third Quarter of 2019 as Compared to the Third Quarter of 2018

-- Net Revenue was $7.7 million which included revenues of both our Diagnostics and Pharma Solutions business for part of the quarter, an increase of 34%; -- Gross Profit was 37%, a decrease compared to 52% primarily due to the acquisition of the BioPharma business and the reduction in the estimate of amounts to be collected resulting from our transition to a new billing and collections contractor. -- Sales & marketing expenses increased $0.7 million to $2.8 million; -- G&A Expenses were $4.5 million as compared to $2.1 million again related principally to our BioPharma acquisition and certain non-cash charges; -- Acquisition-related costs were $0.8 million in the current quarter with no such costs in the prior year; -- Loss from Continuing Operations was $(7.3) million as compared to $(3.0) million; -- Net Loss per basic and diluted share was $(0.19) versus $(0.11); -- Adjusted EBITDA was $(4.2) million as compared to $(1.0) million; and -- Net cash used in operations for the quarter was $(4.8) million as compared to $(1.8) million.

For the Nine Months Ended September 30, 2019 as Compared to the Nine Months Ended September 30, 2018

-- Net Revenue increased to $20.0 million, a 25% improvement; -- Gross Profit decreased to 48% from 53%; -- Sales & Marketing expenses increased $2.0 million or 33%; -- G&A expenses were $9.8 million as compared to $6.0 million due principally to costs associated with the BioPharma acquisition; -- Acquisition-related costs were $2.4 million with no such costs in the comparable period for the prior year; -- Loss from Continuing Operations was $(16.0) million as compared to $(8.0) million; -- Net Loss per Share was $(0.43) as compared to $(0.29); -- Adjusted EBITDA was $(7.7) million as compared to $(3.4) million; and -- Net cash used in operations was $(12.6) million as compared to $(6.8) million.

Cash and cash equivalents were $2.4 million as of September 30, 2019 before the closing of the second tranche financing with Ampersand on October 16th, 2019. From the proceeds received from the second closing with Ampersand, approximately $3.75 million was used to repay the balance in the revolving credit line, $6.02 million was used to repay the note to Cancer Genetics and the balance was used for general corporate purposes including the integration of the BioPharma business. Further, on September 20, 2019, the Company entered into an Equity Distribution Agreement with Oppenheimer & Co. Inc., as sales agent, pursuant to which the Company may, from time to time, issue and sell shares of its common stock with an aggregate offering price of up to $4.8 million.. To date, no shares have been sold under this Agreement.

Adjusted EBITDA (in the attached schedule), which we believe is a meaningful supplemental disclosure that may be indicative of how management and our Board of Directors evaluate Company performance, is defined as income or loss from continuing operations, plus depreciation and amortization, non-cash stock based compensation, interest and taxes, and other non-cash expenses including asset impairment costs, non-recurring acquisition and transition expenses, loss on extinguishment of debt, goodwill impairment, change in fair value of contingent consideration and warrant liability.

RECENT BUSINESS HIGHLIGHTS

Secured Additional Financing via Ampersand Capital Partners and Acquisition of BioPharma Business

Closed on a $13 million Convertible Preferred Stock investment by Ampersand constituting the second tranche of the overall $27 million Convertible Preferred Stock financing provided by Ampersand to Interpace in connection with Interpaces July 15, 2019 acquisition of the BioPharma Business of Cancer Genetics, Inc. (CGIX).

Reimbursement Expansion Announced

In September we announced that we contracted with 3 independent Blue Cross Blue Shield (BCBS) plans in the South and Southwest totaling nearly 5 million covered lives; -- Announced diagnostic contract agreement with BCBS plans of Michigan and California; -- Announced agreement with SelectHealth to provide ThyGeNEXT and ThyraMIR in Utah and Idaho to more than 850,000 members; and; -- Announced that THyGeNEXT and ThyraMIR are now covered by Independence Blue Cross for its nearly 2.5 million members in Philadelphia and Southeastern PA.

Clinical Validation Announcements

-- Announced the publication of two peer-reviewed journal articles and one textbook chapter supporting the clinical utility of ThyGeNEXT when used alone and in combination with ThyraMIR; -- Presented new data on the performance of ThyGeNEXT and ThyraMIR at the American Thyroid Assn Annual Meeting in October; -- Presented new data on the performance of PancraGEN at the American College of Gastroenterology in October; and -- Presented at the World Congress on Thyroid Cancer in Rome on detail outcomes of a study using our thyroid assays in combination with microRNA testing.

Other

-- Entered into a strategic partnership with Genecast to partner biopharma solutions in China; -- Interpace named one of the 50 Most Admired Companies of the Year by Silicon Review; and -- Entered into agreement with Predictive Oncology to evaluate diagnosis of thyroid cancer via AI-driven analyses.

UPDATED NET REVENUE GUIDANCE

Interpace is adjusting its 2019 annual Net Revenue guidance to between $28 and $32 million as we continue to transition the BioPharma business and prepare for our first full year together. Interpace Biosciences is also confirming top-line revenue guidance of $50 million for 2020.

CONFERENCE CALL INFORMATION Interpace will hold a conference call and Webcast on Wednesday, November 13, 2019, at 4:30 pm ET to discuss financial and operational results for the third quarter ended September 30, 2019. Details are as follow:

Date and Time:Wednesday, November 13, 2019 at 4:30 pm ET Dial-in Number (Domestic):(877) 407-0312 Dial-in Number (International):+1 (201) 389-0899 Confirmation Number:13690534 Webcast Access:https://webcasts.eqs.com/interpacedia20190513/en

The webcast replay will be available on the Companys website approximately two hours following completion of the call and archived on the Companys website for 90 days.

About Interpace Biosciences

Interpace Biosciences is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Interpace Diagnostics is a fully integrated commercial and bioinformatics business unit that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management.

Interpace Pharma Solutions provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries and advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.For more information, please visit Interpaces current website at http://www.interpacediagnostics.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Companys future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including believes, estimates, anticipates, expects, plans, projects, intends, potential, may, could, might, will, should, approximately or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Companys control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Companys actual results to be materially different from those expressed or implied by any forward-looking statement, including that there is no assurance that the acquisition of the BioPharma business will be successfully integrated with the Company, that the potential benefits of the acquisition, including future revenues, will be successfully realized, that other potential acquisitions will be successfully consummated, that the Company will be able to maintain its Nasdaq listing and that the Company will be able to meet its revenue projections. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Companys most recent Annual Report on Form 10-K, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contacts: Investor Relations Edison Group Joseph Green (646) 653-7030 jgreen@edisongroup.com

Non-GAAP Financial Measures

In addition to the United States generally accepted accounting principles, or GAAP, results provided throughout this document, Interpace Biosciences has provided certain non-GAAP financial measures to help evaluate the results of its performance. We believe that these non-GAAP financial measures, when presented in conjunction with comparable GAAP financial measures, are useful to both management and investors in analyzing the Companys ongoing business and operating performance. We believe that providing the non-GAAP information to investors, in addition to the GAAP presentation, allows investors to view the Companys financial results in the way that management views financial results.

In this document, we discuss Adjusted EBITDA, a non-GAAP financial measure. Adjusted EBITDA is a metric used by management to measure cash flow of the ongoing business. Adjusted EBITDA is defined as income or loss from continuing operations, plus depreciation and amortization, acquisition related expenses, transition expenses, non-cash stock based compensation, interest and taxes, and other non-cash expenses including asset impairment costs, bad debt expense, loss on extinguishment of debt, goodwill impairment and change in fair value of contingent consideration, and warrant liability. The table below includes a reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure.

INTERPACE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (in thousands, except per share data)

Three Months Ended Nine Months Ended September 30, September 30, -------------------- --------------------- 2019 2018 2019 2018 -------- -------- --------- -------- Revenue, net $ 7,725 $ 5,753 $ 20,005 $ 16,062 Cost of revenue 4,835 2,763 10,489 7,590 - ------ - ------ - ------- - ------ Gross Profit 2,890 2,990 9,516 8,472 Sales and marketing 2,757 2,048 8,127 6,135 Research and development 857 510 2,032 1,528 General and administrative 4,492 2,084 9,790 5,981 Acquisition related expense 838 - 2,534 - Acquisition related amortization expense 995 813 2,621 2,439 Total operating expenses 9,939 5,455 25,104 16,083 Operating loss (7,049 ) (2,465 ) (15,588 ) (7,611 ) Accretion expense (111 ) (248 ) (331 ) (248 ) Other income (expense), net (135 ) (288 ) (12 ) (143 ) - ------ - ------ - ------- - ------ Loss from continuing operations before tax (7,295 ) (3,001 ) (15,931 ) (8,002 ) Provision for income taxes 9 7 19 21 - ------ - ------ - ------- - ------ Loss from continuing operations (7,304 ) (3,008 ) (15,950 ) (8,023 ) Loss from discontinued operations, net of tax (58 ) (34 ) (51 ) (129 ) Net loss $ (7,362 ) $ (3,042 ) $ (16,001 ) $ (8,152 ) - ------ - ------ - ------- - ------ Basic and diluted (loss) income per share of common stock: From continuing operations $ (0.19 ) $ (0.11 ) $ (0.43 ) $ (0.29 ) From discontinued operations (0.00 ) (0.00 ) (0.00 ) (0.00 ) - ------ - ------ - ------- - ------ Net (loss) income per diluted share of common stock $ (0.19 ) $ (0.11 ) $ (0.43 ) $ (0.29 ) - ------ - ------ - ------- - ------ Weighted average number of common shares and common share equivalents outstanding: Basic 38,196 28,215 37,169 28,002 Diluted 38,196 28,215 37,169 28,002

Selected Balance Sheet Data (Unaudited) ($ in thousands)

September December 30, 31, -------- -------- 2019 2018 -------- -------- Cash and cash equivalents $ 2,358 $ 6,068 Total current assets 20,581 17,721 Total current liabilities 17,296 8,492 Total assets 74,673 48,442 Total liabilities 37,915 15,504 Total preferred stock 13,161 - Total stockholders equity 23,597 32,938

Selected Cash Flow Data (Unaudited) ($ in thousands)

For the Nine Months Ended September 30, --------------------- 2019 2018 --------- -------- Net loss $ (16,001 ) $ (8,152 ) Net cash used in operations $ (12,556 ) $ (6,800 ) Net cash used in investing activities (13,921 ) (388 ) Net cash provided by (used in) financing activities 22,767 (9 ) - ------- - ------ Change in cash and cash equivalents (3,710 ) (7,197 ) Cash and equivalents, Beginning 6,068 15,199 Cash and equivalents, Ending $ 2,358 $ 8,002

GAAP to Non-GAAP Reconciliation (Unaudited) ($ in thousands) Quarters Ended Nine Months Ended September 30, September 30, ---------------------- ----------------------- 2019 2018 2019 2018 -- ----- - -- ----- - -- ------ - -- ----- - Loss from continuing operations (GAAP Basis) ($ 7,304 ) ($ 3,008 ) ($ 15,950 ) ($ 8,023 ) Acquisition related expense 838 - 2,534 - Transition expenses 836 - 836 - Depreciation and amortization 1,074 870 2,823 2,580 Stock-based compensation 211 525 1,247 1,564 Bad debt expense - - 499 - Taxes - 7 - 21 Accretion expense 111 248 331 248 Mark to market on warrant liability 10 325 -35 259 Adjusted EBITDA (Non-GAAP Basis) ($ 4,224 ) ($ 1,033 ) ($ 7,715 ) ($ 3,351 ) -- ----- - -- ----- - -- ------ - -- ----- -

Read more from the original source:
Interpace Diagnostics Changes Name to Interpace Biosciences; Announces Plans for Next Phase of Growth and Third Quarter 2019 Financial Results -...

NEW YORK, Nov. 13, 2019 /PRNewswire/ --

KEY FINDINGSThe global metabolomics market is predicted to showcase growth at a CAGR of 11.84% during the projected period. The surging chronic diseases, along with the prevalence of cancer, are the major factors influencing the growth of the global market of metabolomics.

Read the full report: https://www.reportlinker.com/p05826891/?utm_source=PRN

MARKET INSIGHTSThe report includes the segmentation on the basis of application, indication, and product & service.The use of metabolomics in studying cancer would be instrumental as it would result in new biomarkers for cancer, which are further used in the diagnosis of the disease.

Also, advancements in personalized medicine aids in a scientific understanding of diseases like cancer and genetic diseases.The development of methodologies has always been given preference when it comes to research activities in nutrition.

This is set to result in huge market growth opportunities in the global metabolomics market. The metabolomics incurs huge costs in terms of instrumentation, and this factor can limit the market growth.

REGIONAL INSIGHTSThe global market with regard to metabolomics is analyzed on the basis of North America, Europe, Asia Pacific, and the Rest of the World.The North American market region is projected to garner the largest market share by the end of the forecast period.

The region has a large presence of several end-users.The market region of Asia Pacific is estimated to record the highest CAGR for the metabolomics market.

The growth is attributed to the presence of economically diverse countries in the region.

COMPETITIVE INSIGHTSThe market has the presence of key players that aid in the growth and revenue of the market. Some of the key players include, Bruker Corporation, Danaher Corporation (Sciex), Bio-Rad Laboratories, Inc., Biocrates Life Sciences Ag, Creative Proteomics, Apical Scientific Sdn Bhd, etc.

Our report offerings include: Explore key findings of the overall market Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges) Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions Market Segmentation cater to a thorough assessment of key segments with their market estimations Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc. Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc. Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Companies mentioned1. AGILENT TECHNOLOGIES, INC.2. APICAL SCIENTIFIC SDN BHD3. BIOCRATES LIFE SCIENCES AG4. BIO-RAD LABORATORIES, INC.5. BRUKER CORPORATION6. CREATIVE PROTEOMICS7. DANAHER CORPORATION (SCIEX)8. HUMAN METABOLOME TECHNOLOGIES, INC.9. KORE TECHNOLOGY LIMITED10. LECO CORPORATION11. METABOLON INC.12. PERKINELMER, INC.13. SHIMADZU CORPORATION14. THERMO FISHER SCIENTIFIC INC.15. WATERS CORPORATION

Read the full report: https://www.reportlinker.com/p05826891/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

Read the rest here:
The region has a large presence of several end-users.The market region of Asia Pacific is estimated to record the highest CAGR for the metabolomics...

ByKristin Hanson

This article was originally published on Nov. 8 on giving.jhu.edu

Between 2001 and the beginning of 2018, more than 1,500 U.S. military service members lost limbs in the line of duty. Although technology has improved the prosthetic devices these people can use, a stubborn obstacle remains: the fragility of human skin.

"Skin was never meant to hold this kind of pressure," says Lee Childers, the senior scientist for the Extremity Trauma and Amputation Center of Excellence at Brooke Army Medical Center in San Antonio, Texas.

"Think about it like a blister on your foot. It's painful, but you can still get by," he continues. "In an amputation, it's a blister on your residual limb. You can't use your prosthesis until the blister is completely healed. If it's your leg [that is affected], you can't walk for two or three weeks. Think about how that would impact your life."

What if there were a way to make the skin at an amputation site tougher, like the palm of your hand or the sole of your foot? Luis Garza, an associate professor of dermatology at Johns Hopkins and leader of the Veteran Amputee Skin Regeneration Program, is developing a cell therapy that could enable prosthetics wearers to use their devices longer.

"This is an example of personalized medicine," Garza says. "We're taking each person's own cells, growing them up, and inserting them back in."

Garza's postdoctoral research focused on skin stem cells. In 2009, he and his department chair, Sewon Kang, began having conversations about how that work could help the increasing numbers of veterans coming back from war with amputations. Garza and his team received grants from the U.S. Department of Defense, National Institutes of Health, and Maryland Stem Cell Fund that have moved the program forward in the past decade.

Garza's team spent the summer of 2019 testing "normal" subjectsthose without amputationsto perfect the procedure, including the dose, content, method, and frequency of the injections. During one appointment, members of Garza's team took biopsies of skin from a subject's scalp and sole. The cells went to a lab where they were grown under an FDA-approved protocol and passed through quality control tests.

In a second appointment, subjects completed a questionnaire and underwent baseline measurements of their skin's thickness and strength. Garza's team then injected a site on the subjects' skin with the stem cells grown from their cells in the lab.

Image caption: Luis Garza, associate professor of dermatology at Johns Hopkins, leads the Veteran Amputee Skin Regeneration Program.

"We're hoping that these stem cell populations will engraft in the new skin," Garza says.

The subjects returned to Hopkins several months later to go through the questionnaire and measurements once more, and Garza's team documented changes.

Confident in the results they gleaned from the normal subjects, Garza's team enrolled its first subject with an amputation in August. Moving from the normal population to the amputation-affected population quickly unearthed some aspects of the therapy Garza didn't anticipate.

"When we talked with him, he said 'I don't want to mess with my one remaining footdo you have to take skin from there?' And we said, 'Actually, no, we could do your palm,'" Garza says.

His team then tested the biopsy and growth of palm cells from subjects in the normal population. "We're moving away from having our product informed purely by biology to letting our therapy development be shaped by the user."

Although federal grants have supported much of the program's progress, private philanthropy has played a role, too. Corporations like Northrop Grumman, foundations like the Alliance for Veteran Support, and grateful patients with and without ties to the armed forces have contributed nearly $300,000. Those gifts have enabled the program to persevere through gaps between federal grants.

Private funds will be increasingly important as the project enters its next phase: extension to military medical centers around the country. Garza's team must prove that the safeguards to protect cells on their round-trip voyage from a test site to Hopkins are effective. They also must secure approval by local institutional review boards for clinical studies.

"Soldiers are used to getting orders, but you can't order someone to be part of a [medical] study," Garza says. "There are hard medical ethics questions around how to make this open to them but ensure they don't feel obligated. We've been working on that for a year, and we probably have another six months or so to go."

Childers stands ready for whenever the program's extension is a go. He will lead the study at Brooke Army Medical Center and feels motivated by the prospect of helping many of the veterans he works with every day.

"We do everything we can to serve those who serve us. This can enable people to return to duty and be redeployed if they choose," he says. "This is game-changing technology that will have an impact for our service members, but also others who live with amputation."

That population includes the hundreds of thousands of Americans who've undergone amputations for complications of diabetes, who must use a wheelchair, or who wear ankle or foot orthoses for help with walking, among others.

"Having the ability to transform skin anywhere you want to target on the body will have gigantic implications across the entire spectrum of our society in many ways," Childers says.

There's a lot of work to be done before such benefits reach the public, Garza cautions. With continued support from donors and the military community, though, he's optimistic about the program's future.

"The challenges are pretty big, but I think within five years, it could happen," he says. "That's the hope."

Disclaimer: The view(s) expressed herein are those of the author(s) and do not reflect the official policy or position of the Brooke Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of the Air Force and Department of Defense or the U.S. Government.

Here is the original post:
Serving those who serve - The Hub at Johns Hopkins

CHF 32 Million in Milestone Revenues

Multiple Upcoming Catalysts

Execution Across Clinical and Preclinical Neurodegenerative Development Pipeline

LAUSANNE, Switzerland, Nov. 13, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (ACIU), a Swiss-based biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative diseases, today provided a business and clinical update and reported its consolidated financial results for the third quarter of 2019.

Prof. Andrea Pfeifer, Ph.D., CEO of AC Immune, commented: AC Immune, together with our leading pharmaceutical partners, is advancing one of the industrys broadest, most diversified development pipelines targeting neurodegenerative diseases. This quarter, we continued to demonstrate strong progress across our pipeline of potentially best-in-class small molecule, antibody, and vaccine therapeutics, as well as our cutting-edge diagnostic agents. This resulted in milestones achieved totaling CHF 32 million which were comprised of CHF 30 million from Eli Lilly and Company and EUR 2 million (CHF 2.2 million) from Life Molecular Imaging.

Prof. Pfeifer continued, We anticipate multiple catalysts in 2019 and 2020, highlighted by expected Phase 2 data for semorinemab, our anti-Tau antibody partnered with Genentech/Roche, which we anticipate will be the first Phase 2 data available for a Tau-targeted therapy in Alzheimers disease (AD). We also anticipate achieving further progress across our development pipeline with both early and late stage data readouts that we believe will build substantial value for the Company.

AC Immunes unique, multi-pronged approach is designed to address the full spectrum of neurodegenerative diseases. By selectively targeting misfolded pathological proteins both intracellularly and extracellularly, and by creating state-of-the-art diagnostic imaging agents that enable early detection of multiple disease pathologies and tracking of disease progression, AC Immune is pioneering a personalized medicine approach to deliver the right therapy to the right patient at the right time.

Research & Development Highlights

Analysis of Financial Statements for the Three and Nine Months Ended September 30, 2019

About AC ImmuneAC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in Precision Medicine for neurodegenerative diseases. The Company is utilizing two proprietary discovery platforms, SupraAntigenTMand MorphomerTM, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with five currently in clinical trials. It has collaborations with major pharmaceutical companies including Roche/Genentech, Lilly and Janssen Pharmaceuticals Inc.

As a strategic leader in the field of neurodegenerative diseases, AC Immune has developed a five-point Roadmap to Successful Therapies for Neurodegenerative Diseases that recognizes the importance of treating earlier, targeting Tau, focusing on more homogeneous patient populations, precision medicine and exploring neuroinflammation as a target.

For further information, please contact:

Forward-looking statementsThis press release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immunes strategies or expectations. In some cases, you can identify these statements by forward-looking words such as may, might, will, should, expects, plans, anticipates, believes, estimates, predicts, projects, potential, outlook or continue, and other comparable terminology. Forward-looking statements are based on managements current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions Item 3. Key InformationRisk Factors and Item 5. Operating and Financial Review and Prospects in AC Immunes Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

Story continues

Balance Sheets

Statements of Income/(Loss)

Statements of Comprehensive Income/(Loss)

Reconciliation of Income/(Loss) to Adjusted Income/(Loss) and Earnings/(Loss) Per Share to Adjusted Earnings/(Loss) Per Share

(a) Reflects non-cash expenses associated with share-based compensation for equity awards issued to Directors, Management and employees of the Company. This expense reflects the awards fair value recognized for the portion of the equity award which is vesting over the period.

(b) Reflects foreign currency remeasurement gains and losses for the period, predominantly impacted by the change in the exchange rate between the US Dollar and the Swiss Franc.

(c) Effective interest expense for the period relates to the accretion of the Companys convertible loan in accordance with the effective interest method.

(d) Change in fair value of conversion feature that is bifurcated from the convertible loan host debt with Lilly.

For the three and nine months ended September 30, 2019, adjustments increased net income and decreased net income by CHF 0.6 million and CHF 0.9 million compared with decreases to the net losses by CHF 1.9 million and CHF 3.0 million for the comparable periods in 2018, respectively. The Company recorded CHF 0.9 million and CHF 2.0 million for the three and nine months, respectively, for share-based compensation expenses. There were foreign currency remeasurement gains of CHF 0.3 million and remeasurement losses of CHF 0.3 million, respectively, related to foreign currency fluctuations. The Company recorded nil and CHF 1.4 million for amortization of effective interest for the three and nine months ended September 30, 2019, respectively. Finally, the Company recognized nil and a CHF 4.5 million gain for the change in fair value of the liability related to the conversion feature.

Read more from the original source:
AC Immune Q3 2019 Financial Results and Business Update - Yahoo Finance

Personalized Medicine Market Overview:

The recent report added by Verified Market Research gives a detailed account of the drivers and restraints in the Personalized Medicine Market. The research report, titled [Personalized Medicine Market Size and Forecast to 2026] presents a comprehensive take on the overall market. Analysts have carefully evaluated the milestones achieved by the Personalized Medicine Market and the current trends that are likely to shape its future. Primary and secondary research methodologies have been used to put together an exhaustive report on the subject. Analysts have offered unbiased outlook on the Personalized Medicine Market to guide clients toward a well-informed business decision.

The comprehensive research report has used Porters five forces analysis and SWOT analysis to give the readers a fair idea of the direction the Personalized Medicine Market is expected to take. The Porters five forces analysis highlights the intensity of the competitive rivalry while the SWOT analysis focuses on explaining strengths, weaknesses, opportunities, and threats present in the Personalized Medicine Market. The research report gives an in-depth explanation of the trends and consumer behavior pattern that are likely to govern the evolution of the Personalized Medicine Market.

Request a Sample Copy of this report @https://www.verifiedmarketresearch.com/download-sample/?rid=7106&utm_source=MG24&utm_medium=AK

Key Players Mentioned in the Personalized Medicine Market Research Report:

Personalized Medicine Market: Regional Segmentation

For a deeper understanding, the research report includes geographical segmentation of the Personalized Medicine Market. It provides an evaluation of the volatility of the political scenarios and amends likely to be made to the regulatory structures. This assessment gives an accurate analysis of the regional-wise growth of the Personalized Medicine Market.

Personalized Medicine Market: Research Methodology

The research methodologies used by the analysts play an integral role in the way the publication has been collated. Analysts have used primary and secondary research methodologies to create a comprehensive analysis. For an accurate and precise analysis of the Personalized Medicine Market, analysts have bottom-up and top-down approaches.

Ask for Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7106&utm_source=MG24&utm_medium=AK

Table of Content

1 Introduction of Personalized Medicine Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Personalized Medicine Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Personalized Medicine Market, By Deployment Model

5.1 Overview

6 Personalized Medicine Market, By Solution6.1 Overview

7 Personalized Medicine Market, By Vertical

7.1 Overview

8 Personalized Medicine Market, By Geography8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Personalized Medicine Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/global-personalized-medicine-market-size-and-forecast-to-2026/?utm_source=MG24&utm_medium=AK

We also offer customization on reports based on specific client requirement:

1-Freecountry level analysis forany 5 countriesof your choice.

2-FreeCompetitive analysis of any market players.

3-Free 40 analyst hoursto cover any other data points

About Us:

Verified Market Research has been providing Research Reports, with up to date information, and in-depth analysis, for several years now, to individuals and companies alike that are looking for accurate Research Data. Our aim is to save your Time and Resources, providing you with the required Research Data, so you can only concentrate on Progress and Growth. Our Data includes research from various industries, along with all necessary statistics like Market Trends, or Forecasts from reliable sources.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email:sales@verifiedmarketresearch.com

Tag: Personalized Medicine Market Size, Personalized Medicine Market Growth, Personalized Medicine Market Analysis, Personalized Medicine Market Forecast, Personalized Medicine Market Outlook, Personalized Medicine Market Trends, Personalized Medicine Market Research, Personalized Medicine Market Report

Read the original post:
Personalized Medicine Market Size 2019 By Top Key Players, By Type and Application, Forecast to 2026 - Markets Gazette 24

Data Bridge Market Research Adds Gene Editing Tools Market Industry Trends and Forecast to 2026 new report to its research database. The report spread No of pages:350 No of Figures:60 No of Tables:220 in it.

This report proves to be a useful guide for the individuals related to Gene Editing Tools market as it accommodates data such as advancement patterns, competitive scene examination, and key locales improvement status. Few of the major competitors currently working in theThermo Fisher Scientific Inc.; CRISPR Therapeutics; Editas Medicine; National Human Genome Research Institute; Intellia Therapeutics, Inc.; Merck KGaA; Horizon Discovery Ltd.; GeneCopoeia, Inc.; ERS Genomics; Takara Bio Inc.; New England Biolabs; GenScript among others.

Get a Sample PDF of Gene Editing Tools Report @ (Note: Kindly use your business/corporate email id to get priority): https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-gene-editing-tools-market

Global Gene Editing Tools Market is expected to register a healthy CAGR of 17.63% in the forecast period of 2019-2026. The report contains data from the base year of 2018 and the historic year of 2017. This rise in market value can be attributed to the growing preferences in demands for personalized medicine.

The examination is an ideal blend of both quantitative and qualitative data featuring key market augmentations, challenges that industry and rivalry are trying alongside segmentation and new opportunities accessible and pattern in the Gene Editing Tools Market.

Research strategies and tools used of Gene Editing Tools Market:

This Gene Editing Tools market research report helps the readers to know about the overall market scenario, strategy to further decide on this market project. It utilizes SWOT analysis, Porters Five Forces Analysis and PEST analysis.

Breakdown of Gene Editing Tools Market:

The Gene Editing Tools market report performs segmentation which is done on the basis of type, end-user, and manufacturers and applications to fully and deeply research and reveal market profile and prospects.

Understands the Latest Trend of Gene Editing Tools:

Global Gene Editing Tools Market By Product (CRISPR/Cas9, ZFNs, TALENs, Viral Systems, Transposon Systems, Others), Application (Veterinary Medicine, Cell Line Engineering, Bioremediation, Food & Brewing Development, Food Waste Management, Bio Sensing Development, Others), Disease Application (Sickle Cell Disease, Heart Disease, Diabetes, Alzheimers Disease, Obesity, Others), End-User (Biotech & Pharma Companies, CROs, Academic & Research Institutes, Food Industry, Others), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Industry Trends and Forecast to 2026

Regional Insights of Gene Editing Tools:

Regional analysis helps the market players to take an exhaustive assessment of the Gene Editing Tools market region wise so that it becomes easy for them to distinguish and investigate the developing pattern and hidden opportunities all over the world.

The Gene Editing Tools market covers regions such as- South America, North America, Europe, Asia-Pacific, Middle East, and Africa.

Chapter Details of Gene Editing Tools

Part 01: Executive Summary

Part 02: Scope of The Report

Part 03: Gene Editing Tools Market Landscape

Part 04: Gene Editing Tools Market Sizing

Part 05: Gene Editing Tools Market Segmentation By Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape

Part 08: Geographic Landscape

Part 09: Decision Framework

Part 10: Drivers and Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

View Detailed Table of Content @ https://www.databridgemarketresearch.com/toc/?dbmr=global-gene-editing-tools-market

What does this report offer? -:

Developing patterns alongside critical drivers, difficulties and conceivable outcomes.

Fortifies decision making capabilities of market players.

Statistics of the market in form of graphs, pictures, pie-charts and tables.

Detailed knowledge of Gene Editing Tools market.

Competitive Evaluation:

The Gene Editing Tools research report highlights the import market Dynamics of the Industry, Definitions and Software of this Series and Also business arrange of this Market. Future prospects of this industry and Market scenario. Also, Prime strategical tasks on the current Market including improvements, mergers, acquisitions and Partnership, etc.

Analysis of the Market with Analytical tools

The report additionally accompanies an investigation of the business focused scene combined with a profoundly nitty gritty SWOT examination also.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

Go here to read the rest:
Gene Editing Tools Market Continuous Excellent Growth | Intellia Therapeutics, Inc.; Merck KGaA; Horizon Discovery - Eastlake Times

PRP, or platelet-rich plasma, is part of a revolution in medicine. PRP contains an abundance of growth factors that play a valuable role in healing many ailments. The PRP technology has been developing for the benefit of patients, resulting in improved outcome and great results.

Platelet-rich plasma has evolved over the past 15 years from an experimental treatment and an idea that concentrated platelets can heal injuries to an everyday treatment that benefits so many. Platelets are concentrated by taking your blood in a tube or syringe and spinning the blood in a high-speed centrifuge that causes the components of blood to separate, including the red blood cells, white blood cells and platelets. The first generation of platelets involved one or two spins to separate the platelets, often including an anticoagulant to prevent clotting and solidifying of the platelets so it can be spread as a liquid around the target. This PRP has been effective for a range of musculoskeletal conditions. The second generation of PRP involves formation of a platelet-rich fibrin matrix (PRFM) that is valuable as a gel that can be applied to wounds, surgical sites and for dental conditions.

The third generation of PRP, also called CGF or concentrated growth factors,

was first developed and described in 2006 by an Italian physician (Dr. Sacco) and has recently become widely available in the United States with the Medifuge centrifuge. With a single spin, the blood is spun at multiple speeds, which concentrates the platelets while also isolating cells that express CD34+. This is a type of stem cell that greatly enhances the effectiveness of the platelets. The other advantage of this third-generation PRP is that without anticoagulants the platelets can be applied quickly as a liquid to apply to injured tendons and ligaments or for cosmetic benefit. By waiting a few minutes the platelets solidify, which is great for applying to wounds. Even when applied as a liquid, the third generation platelets solidify soon after injected, which helps attach the platelets to the area injected. This allows the platelets to provide growth factors for a longer duration to increase effectiveness.

There are many applications for this advanced PRP. Ligament and tendon injuries respond very well to PRP. These injuries often do not heal spontaneously because the ligaments and tendons do not get good blood flow. With PRP and its accompanying growth factors, the tendon and ligament is able to finally heal, providing long-term relief. In contrast to a steroid injection, which provides short-term relief and may contribute to tissue degeneration, PRP helps build and strengthen tissue and provides long-term relief.

To clarify, tennis elbow, golfers elbow, rotator cuff tendonitis, wrist tendonitis, iliotibial band syndrome, Osgood-Schlatters and Achilles tendonitis are all examples of tendon injuries characterized by weakening of the tendon fibers or even partial tears. PRP strengthen the tendon and heals all of these conditions.

Ligament injuries include all joint sprains and strains such as ankle sprains, shoulder strains, etc. The hallmark of joint arthritis is weakening of the ligaments that leads to wear and tear of the joint, with a cascade of cartilage erosion that leads to bone spurs, then joint space narrowing and eventually bone on bone. Any time you see a bone spur, chances are that there is a loose ligament that created the conditions that led to that spur. Platelets heal the ligaments so that the joint is more stable and the arthritic pain is relieved and recurrent ankle sprains stop recurring.

Thus, PRP is very effective for arthritic joints, including knee arthritis, hip arthritis and shoulder arthritis among others. The PRP is effective at strengthening the joint capsule that is comprised of ligaments and can provide support for the joint cartilage. Even with severe bone-on-bone arthritis, PRP can help strengthen the ligaments around the joint, which helps reduce pain.

PRP can also help you improve your appearance. With the vampire facial you get the benefit of the healing growth factors, which lead to increased collagen and blood flow for skin rejuvenation. The great aspect of this treatment is that this is a very natural way to naturally enhance your skin. Without undergoing surgery you can achieve a youthful appearance. So while stars such as Bar Rafaeli and Kim Kardashian have used platelets to enhance their appearance, the vampire facial is accessible to you and will give your skin a healthy, revitalized feeling. Everyone has an inner beauty. PRP helps your outer beauty so it is in sync with your inner beauty.

There are other cosmetic benefits to platelets. The growth factors that the platelets release can heal scars. This includes unsightly scars after a surgery or a laceration. Growing collagen within the scar will usually improve its appearance. Acne scars, which are tiny holes along the skin surface, are filled in with platelets. Burn scars may not be totally eliminated with PRP, but the growth factors can have dramatic effects on the appearance of these scars.

Another cosmetic benefit of PRP is hair growth. PRP leads to increased hair follicle formation increasing the hair density. While not practical for total hair loss, PRP is excellent for treating thinning hair in men and women. The best part is that you are stimulating the follicle growth with your own platelets without the use of medications or other invasive procedures. So if you run your hand through your hair and you feel it is thinner than you would like, PRP may be for you.

PRP is abundant, safe and the worlds most sophisticated repair system. Nothing else comes close to its amazing properties. PRP is a powerful source of growth factors. Whats best is that it comes from your own body so you are healing your own body with your own platelets. Whether you have an injury that needs the healing benefit of platelets, or if you want to enhance your appearance, promote hair growth or improve a scar, or for other challenges that can be enhanced with platelets, you should consider PRP to improve your quality of life. The success of PRP has been enhanced with the new technology of third-generation PRP. The concentrated growth factors (CGF) optimize platelets that are enhanced by stem cells for maximal benefit.

Dr. Slaten is a pain wellness physician in Ridgewood. For more than 20 years he has been practicing regenerative techniques with great skill and an open mind. Check out his website at http://www.njprp.com for more information.

See the article here:
The Third Generation of PRP Is Here - Jewish Link of New Jersey